Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
Completed
1,340 enrolled
Vaccine Therapy in Treating Patients With Multiple Myeloma
Phase 2 Completed
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
Completed
902 enrolled
BMT CTN 0102
Phase 3 Completed
710 enrolled 19 charts
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
Phase 2 Completed
70 enrolled
Testing a Spanish Version of a Patient Toxicity Questionnaire
Completed
112 enrolled
Experimental Bone Marrow Transplant Protocol
Phase 2 Completed
14 enrolled
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
Phase 2 Completed
50 enrolled 12 charts
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 3 Completed
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
Phase 1 Completed
42 enrolled
Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma
Phase 1/2 Completed
56 enrolled
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 3 Completed
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
Phase 2 Completed
30 enrolled
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Completed
35 enrolled
Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma
Phase 1/2 Completed
30 enrolled
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
36 enrolled
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
Phase 3 Completed
280 enrolled
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Phase 2 Completed
Rituximab in Treating Patients With Multiple Myeloma
Phase 2 Completed
Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma
Phase 2 Completed
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Phase 2 Completed
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
Phase 2 Completed
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Completed
Interleukin-12 in Treating Patients With Multiple Myeloma
Phase 2 Completed
40 enrolled
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
Phase 2 Completed
Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
Phase 3 Completed
200 enrolled
Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer
Phase 3 Completed
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Phase 1/2 Completed
30 enrolled
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
Phase NA Completed
30 enrolled
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Phase 1 Completed
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
36 enrolled
Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
Phase 2 Completed
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
Phase 2 Completed
75 enrolled
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Phase 1 Completed
40 enrolled
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Phase 2 Completed
45 enrolled
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
Phase 1/2 Completed
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
Phase 1 Completed
20 enrolled
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
Phase 2 Completed
82 enrolled
Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment
Phase 2 Completed
48 enrolled
Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 1/2 Completed
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
Phase 2 Completed
25 enrolled
HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies
Phase 1 Completed
35 enrolled